Ipamorelin

II. What is this compound?

Ipamorelin (NNC 26-0161) is a synthetic pentapeptide. It is five amino acids in this order: Aib-His-D-2-Nal-D-Phe-Lys-NH2. Its molecular weight is 711.9 Da. Novo Nordisk developed it in the late 1990s. It belongs to the growth hormone secretagogue (GHS) family. These are compounds that trigger GH release through specific receptors.

What set it apart at launch was restraint. Earlier GHS compounds like GHRP-2 and GHRP-6 GHRP-6 growth hormone secretagogue (GHS) / ghrelin receptor agonist Ghrelin mimetic hexapeptide — strongest appetite stimulation among GHRPs hit many hormonal pathways at once. Ipamorelin targets the ghrelin receptor GHSR-1a with few off-target effects. This precision comes from unusual building blocks: D-amino acids and aminoisobutyric acid. These also give the peptide a half-life of about two hours, which affects how often it appears in research.

Studies indicate the selectivity holds past the receptor: minimal impact on cortisol and prolactin at physiological doses [2] PMID: 9758556 . This clean profile made Ipamorelin a good fit for preclinical studies of the GH-ghrelin axis. Researchers often use it to examine muscle tissue and metabolic parameters.

In research settings, people usually inject it under the skin or into muscle. Its short half-life means it is often studied with longer-acting compounds like CJC-1295 CJC-1295 growth hormone releasing hormone (GHRH) analogue Growth hormone-releasing hormone analogue . Two keys, two locks, one GH signal. How that key turns inside the pituitary is where the mechanism comes in.

III. How it works

Most growth hormone secretagogues are blunt tools. They raise GH, but also raise cortisol, prolactin, and other hormones. Ipamorelin was built as a scalpel instead. Research suggests this peptide targets the ghrelin receptor [3] PMID: 9758556 . This receptor is the same molecular "on button" your body uses for hunger. But Ipamorelin does not trigger hunger itself. This selectivity is the key point.

When Ipamorelin binds ghrelin receptors on pituitary cells, it starts a cellular signal chain. This chain tells the cells to release stored growth hormone [4] PMID: 9758556 . It uses the same path earlier secretagogues used. The difference is what happens everywhere else.

What Ipamorelin *doesn't* do matters most: studies show minimal effects on cortisol or prolactin at physiological doses [5] PMID: 9758556 . This profile separates it from first-generation compounds. Anyone studying growth hormone soon learns a standard tradeoff: selectivity usually means weaker effects. Preclinical data suggests Ipamorelin may offer both.

That leaves a truly open question: does cleaner signaling actually produce cleaner outcomes? This matters for anyone designing a protocol around growth hormone optimization. Testing it is where the benefits evidence comes in.

• Selective GH release via ghrelin receptor (GHSR-1a) agonism
  PMID 9758556
• Minimal effect on cortisol and prolactin (selectivity advantage)
  PMID 9758556

IV. Research Findings

Preclinical research suggests Ipamorelin may support muscle protein synthesis by releasing growth hormone. Growth hormone is a known driver of anabolic processes. It holds nitrogen, raises protein synthesis, and promotes skeletal muscle cell growth. The real question is whether the peptide's clean signal delivers these downstream effects.

In animal models, it seems to move that needle. Studies have shown increases in lean tissue mass after Ipamorelin [6] PMID: 9758556 . This is strictly preclinical. The translation to human physiology has never been validated in controlled trials.

Body composition tells a parallel story from the other side. Growth hormone drives lipolysis — the breakdown of stored fat — and raises metabolic rate [7] PMID: 9758556 . Animal studies suggest Ipamorelin may favor fat loss while sparing lean tissue. Researchers would find this advantage genuine if it holds in human research.

Sleep quality is another area of interest. Honesty requires a clear line here. Anecdotal reports describe improvements, plausibly because growth hormone peaks during deep sleep. But no peer-reviewed studies have documented Ipamorelin's effect on sleep [8] PMID: 9758556 . Those reports remain stories, not evidence.

The quietest benefit sits in the design: fewer unexpected endocrine disruptions across longer protocols. This makes selectivity a key feature. Testing that logic against real outcomes is what the next stage of research is for.

• muscle-growth preclinical
  PMID 9758556
• fat-loss preclinical
  PMID 9758556
• sleep anecdotal

V. Dosage Context Explained

Every dose figure for Ipamorelin comes from preclinical animal studies or informal human reports. None come from controlled clinical trials. This difference shapes how you should read all the numbers.

In animal research, doses vary by model organism, study design, and objectives [9] PMID: 9758556 . Typical preclinical dosing uses micrograms per kilogram of body weight, not absolute amounts. Direct extrapolation to humans carries big uncertainty. Differences in pharmacokinetics and receptor sensitivity intervene at every step.

Informal human reports describe subcutaneous doses of 200–300 micrograms per injection. People give it one to three times daily. These figures circulate widely online, but circulation is not validation. The pharmacokinetics do support one idea: the two-hour half-life suggests more frequent dosing than longer-acting GH secretagogues. This is a practical thought for research design, but it is not clinical guidance.

Researchers must set dosing parameters from their own study designs, rules, and the literature. They must also accept that this work is purely experimental. With that framing, the safety picture becomes the obvious next question.

• Administration Routes

  subcutaneous

  Range

  200–300 mcg per injection, 1–3x daily

  anecdotal human use; animal study doses vary

  PMID 9758556

VI. Side Effects: Research Context

The side effect profile for Ipamorelin comes mostly from anecdotes, not controlled studies. This is a critical difference. Without systematic records, incidence rates and severity remain unclear.

Mild headache is the most common report. People describe it as brief and occurring after the shot. Flushing — brief redness and warmth, maybe a local vessel response — also appears in reports. At higher doses, some accounts mention water retention. This matches growth hormone's known effects on sodium and fluid balance [10] PMID: 9758556 .

Two theoretical warnings frame the caution list: active malignancy (growth hormone helps cells grow) and conditions with existing GH excess, like acromegaly or gigantism. Past these mechanistic worries sits a bigger unknown: the long-term side effect profile in humans has never been mapped. This is why the compound stays in research settings. Where regulators draw the lines comes next.

• mild headache (anecdotal)
• flushing immediately post-injection (anecdotal)
• water retention at high doses (anecdotal)

VII. Frequently Asked Questions